BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) is a blank-check company focused on the healthcare and life sciences sector that completed its initial public offering in 2021. The company filed an 8-K with the Securities and Exchange Commission on June 8, 2023, under accession number 0001193125-23-163519, documenting a material event during its post-IPO lifecycle. BioPlus is among the cohort of healthcare-oriented SPACs that came to market during the 2020–2022 surge in blank-check issuance, with a mandate to identify and complete a qualifying business combination with a target in the life sciences space. Sign up for full data on SpacDesk to access complete filing history, sponsor details, and deal-status analytics for BIOS and hundreds of other SPACs.